Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity

BACKGROUND: Multiple vaccines have been approved since August 2021 to prevent infection with SARS-CoV-2; however, 20–40% of immunocompromised people fail to develop SARS-CoV-2 spike antibodies after COVID-19 vaccination and remain at high risk of infection and more severe illness than non-immunocomp...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez-Bocco, Isabel H., Beluch, Katherine, Cho, Alyssa, Lahoud, Chloe, Reyes, Fabiola A., Moshovitis, Dimitrios G., Unger-Mochrie, Gillian M., Wang, Wei, Hammond, Sarah P., Manne-Goehler, Jennifer, Koo, Sophia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273764/
https://www.ncbi.nlm.nih.gov/pubmed/37328890
http://dx.doi.org/10.1186/s40814-023-01325-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273764/
https://www.ncbi.nlm.nih.gov/pubmed/37328890
http://dx.doi.org/10.1186/s40814-023-01325-y

Ejemplares similares